Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**VMK223** is a heat-treated extract derived from the cell wall of *Bifidobacterium breve*, classified as a postbiotic. It primarily consists of a low molecular weight storage polysaccharide (including β-glucans) and is designed to improve immune and endocrine markers of intestinal epithelial barrier function[1][3]. VMK223 interacts with toll-like receptors (TLR2 and TLR4) on intestinal epithelial cells, potentially modulating the function of the intestinal barrier by limiting gut permeability and preventing microbial translocation[1]. Supplementation with VMK223 has demonstrated significant reductions in systemic inflammatory markers (C-reactive protein [CRP], interleukin 6 [IL-6], tumor necrosis factor alpha [TNF-α]), reduced cortisol, and improved levels of sex hormones (progesterone, oestradiol, estriol, DHEA) and human growth hormone in clinical studies, especially in females over age 40[1][3]. The extract is orally administered and may be promising for conditions linked to gut dysbiosis, inflammation, and hormone imbalance[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VMK223.